{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T14:10:22Z","timestamp":1745849422249},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2022,6,9]],"date-time":"2022-06-09T00:00:00Z","timestamp":1654732800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,6,9]],"date-time":"2022-06-09T00:00:00Z","timestamp":1654732800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum Halle (Saale)"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatologie"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title><jats:p>Zu den schweren, blasenbildenden Arzneimittelreaktionen an der Haut geh\u00f6ren das Stevens-Johnson-Syndrom (SJS) und die toxisch epidermale Nekrolyse (TEN). Allopurinol, Antikonvulsiva, Sulfonamidantibiotika und nichtsteroidale Antirheumatika vom Oxicam-Typ sind wiederholt als Ausl\u00f6ser beschrieben. Zunehmend r\u00fccken auch Immuntherapien als Ausl\u00f6ser schwerer Hautreaktionen in den Fokus. Vorgestellt werden 2\u00a0Patienten mit bull\u00f6sen Hauterscheinungen nach Gabe des Checkpointinhibitors Pembrolizumab. Da das klinische Bild nicht immer eine zweifelsfreie Einordnung zul\u00e4sst, ist eine histologische Mitbeurteilung vielfach unverzichtbar.<\/jats:p>","DOI":"10.1007\/s00105-022-05018-0","type":"journal-article","created":{"date-parts":[[2022,7,5]],"date-time":"2022-07-05T11:09:06Z","timestamp":1657019346000},"page":"959-964","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Bull\u00f6se Arzneimittelreaktion nach Gabe von Pembrolizumab\u00a0\u2013 2\u00a0Fallberichte"],"prefix":"10.1007","volume":"73","author":[{"given":"L.","family":"Golle","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Michl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Kreft","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,6,9]]},"reference":[{"key":"5018_CR1","doi-asserted-by":"publisher","first-page":"4023","DOI":"10.1158\/1078-0432.CCR-15-2872","volume":"22","author":"SM Goldinger","year":"2016","unstructured":"Goldinger\u00a0SM, Stieger\u00a0P, Meier\u00a0B, Micaletto\u00a0S, Contassot\u00a0E, French\u00a0LE, Dummer\u00a0R (2016) Cytotoxic cutaneous adverse drug reactions during anti-PD\u20111 therapy. Clin Cancer Res 22:4023\u20134029","journal-title":"Clin Cancer Res"},{"key":"5018_CR2","doi-asserted-by":"publisher","first-page":"e183","DOI":"10.1111\/ijd.14811","volume":"59","author":"NJ Maloney","year":"2020","unstructured":"Maloney\u00a0NJ, Ravi\u00a0V, Cheng\u00a0K, Bach\u00a0DQ, Worswick\u00a0S (2020) Stevens-Johnson syndrome and toxic epidermal necrolysis-like reactions to checkpoint inhibitors: a\u00a0systematic review. Int J Dermatol 59:e183\u2013e188","journal-title":"Int J Dermatol"},{"key":"5018_CR3","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1159\/000492172","volume":"10","author":"P Chirasuthat","year":"2018","unstructured":"Chirasuthat\u00a0P, Chayavichitsilp\u00a0P (2018) Atezolizumab-induced Stevens-Johnson syndrome in a\u00a0patient with non-small cell lung carcinoma. Case Rep Dermatol 10:198\u2013202","journal-title":"Case Rep Dermatol"},{"key":"5018_CR4","doi-asserted-by":"publisher","first-page":"1798","DOI":"10.1016\/j.jtho.2018.05.031","volume":"13","author":"N Haratake","year":"2018","unstructured":"Haratake\u00a0N, Tagawa\u00a0T, Hirai\u00a0F, Toyokawa\u00a0G, Miyazaki\u00a0R, Maehara\u00a0Y (2018) Stevens-Johnson syndrome induced by pembrolizumab in a\u00a0lung cancer patient. J\u00a0Thorac Oncol 13:1798\u20131799","journal-title":"J Thorac Oncol"},{"key":"5018_CR5","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1111\/ddg.13876_g","volume":"17","author":"R Reschke","year":"2019","unstructured":"Reschke\u00a0R, Mockenhaupt\u00a0M, Simon\u00a0JC, Ziemer\u00a0M (2019) Schwere bull\u00f6se Exantheme unter Therapie mit Checkpoint-Inhibitoren \u2013 zumeist schwere bull\u00f6se lichenoide Arzneimittelexantheme. J\u00a0Dtsch Dermatol Ges 17:943\u2013949","journal-title":"J Dtsch Dermatol Ges"},{"key":"5018_CR6","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1080\/14740338.2019.1619693","volume":"18","author":"P Aggarwal","year":"2019","unstructured":"Aggarwal\u00a0P (2019) Disproportionality analysis of bullous pemphigoid adverse events with PD\u20111 inhibitors in the FDA adverse event reporting system. Expert Opin Drug Saf 18:623\u2013633","journal-title":"Expert Opin Drug Saf"},{"issue":"2","key":"5018_CR7","doi-asserted-by":"publisher","first-page":"100478","DOI":"10.1016\/j.currproblcancer.2019.05.001","volume":"44","author":"R Kumar","year":"2020","unstructured":"Kumar\u00a0R, Bhandari\u00a0S (2020) Pembrolizumab induced toxic epidermal necrolysis. Curr Probl Cancer 44(2):100478. https:\/\/doi.org\/10.1016\/j.currproblcancer.2019.05.001","journal-title":"Curr Probl Cancer"},{"issue":"3","key":"5018_CR8","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.jdcr.2017.09.028","volume":"4","author":"LL Griffin","year":"2018","unstructured":"Griffin\u00a0LL, Cove-Smith\u00a0L, Alachkar\u00a0H, Radford\u00a0JA, Brooke\u00a0R, Linton\u00a0KM (2018) Toxic epidermal necrolysis (TEN) associated with the use of nivolumab (PD\u20111 inhibitor) for lymphoma. JAAD Case Rep 4(3):229\u2013231","journal-title":"JAAD Case Rep"},{"issue":"5","key":"5018_CR9","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1177\/1078155219890659","volume":"26","author":"ZR Cai","year":"2019","unstructured":"Cai\u00a0ZR, Lecours\u00a0J, Adam\u00a0JP, Marcil\u00a0I, Blais\u00a0N, Dallaire\u00a0M, Belisle\u00a0A, Mathieu\u00a0A (2019) Toxic epidermal necrolysis associated with pembrolizumab. J\u00a0Oncol Pharm Pract 26(5):1259\u20131265","journal-title":"J Oncol Pharm Pract"},{"issue":"30","key":"5018_CR10","doi-asserted-by":"publisher","first-page":"2746","DOI":"10.1200\/JCO.18.02141","volume":"37","author":"GS Phillips","year":"2019","unstructured":"Phillips\u00a0GS, Wu\u00a0J, Hellmann\u00a0MD, Postow\u00a0MA, Rizvi\u00a0NA, Freites-Martinez\u00a0A, Chan\u00a0D, Dusza\u00a0S, Motzer\u00a0RJ, Rosenberg\u00a0JE, Callahan\u00a0MK, Chapman\u00a0PB, Geskin\u00a0L, Lopez\u00a0AT, Reed\u00a0VA, Fabbrocini\u00a0G, Annunziata\u00a0MC, Kukoyi\u00a0O, Pabani\u00a0A, Yang\u00a0CH, Chung\u00a0WH, Markova\u00a0A, Lacouture\u00a0ME (2019) Treatment outcomes of immune-related cutaneous adverse events. J\u00a0Clin Oncol 37(30):2746\u20132758","journal-title":"J Clin Oncol"},{"issue":"7","key":"5018_CR11","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1111\/cup.13262","volume":"45","author":"T Dolkar","year":"2018","unstructured":"Dolkar\u00a0T, Trinidad\u00a0CM, Nelson\u00a0KC, Amaria\u00a0RN, Nagarajan\u00a0P, Torres-Cabala\u00a0CA, Ivan\u00a0D, Prieto\u00a0VG, Tetzlaff\u00a0MT, Curry\u00a0JL, Aung\u00a0PP (2018) Dermatologic toxicity from novel therapy using antimicrobial peptide LL-37 in melanoma: a detailed examination of the clinicopathologic features. J\u00a0Cutan Pathol 45(7):539\u2013544","journal-title":"J Cutan Pathol"},{"issue":"4","key":"5018_CR12","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1111\/cup.12876","volume":"44","author":"KL Vivar","year":"2017","unstructured":"Vivar\u00a0KL, Deschaine\u00a0M, Messina\u00a0J, Divine\u00a0JM, Rabionet\u00a0A, Patel\u00a0N, Harrington\u00a0MA, Seminario-Vidal\u00a0L (2017) Epidermal programmed cell death-ligand 1 expression in TEN associated with nivolumab therapy. J\u00a0Cutan Pathol 44(4):381\u2013384","journal-title":"J Cutan Pathol"},{"issue":"4","key":"5018_CR13","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1097\/DAD.0000000000001527","volume":"42","author":"S Robinson","year":"2020","unstructured":"Robinson\u00a0S, Saleh\u00a0J, Curry\u00a0J, Mudaliar\u00a0K (2020) Pembrolizumab-induced Stevens-Johnson syndrome\/toxic epidermal necrolysis in a\u00a0patient with metastatic cervical squamous cell carcinoma: a case report. Am J Dermatopathol 42(4):292\u2013296","journal-title":"Am J Dermatopathol"}],"container-title":["Die Dermatologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-022-05018-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00105-022-05018-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-022-05018-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,25]],"date-time":"2022-11-25T11:04:57Z","timestamp":1669374297000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00105-022-05018-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,9]]},"references-count":13,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["5018"],"URL":"https:\/\/doi.org\/10.1007\/s00105-022-05018-0","relation":{},"ISSN":["2731-7005","2731-7013"],"issn-type":[{"value":"2731-7005","type":"print"},{"value":"2731-7013","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,9]]},"assertion":[{"value":"18 May 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"L.\u00a0Golle, C.\u00a0Michl und B.\u00a0Kreft geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien. F\u00fcr Bildmaterial oder anderweitige Angaben innerhalb des Manuskripts, \u00fcber die Patienten zu identifizieren sind, liegt von ihnen und\/oder ihren gesetzlichen Vertretern eine schriftliche Einwilligung vor.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}